Impact of Duodenal Pathology on Oral Drug Bioavailability and Disease Outcomes in Pediatric Crohn's Disease.
Rebecca CasiniCarrie A VyhlidalJulia M BrackenAshley K ShermanAtif A AhmedVivekanand SinghVeronica WilliamsValentina ShakhnovichPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
For children with Crohn's disease, duodenal pathology, marked by villous blunting, increased the risk of sub-therapeutic 6-TGN levels, despite higher azathioprine dosing during the first year post-diagnosis. Lower hemoglobin and BMI z-scores at 9 months post-diagnosis suggest the impaired absorption/bioavailability of nutrients, as well as oral drugs, in children with duodenal disease.